DLL3 and neuroendocrine carcinoma: Despite the limited sample size, a trend toward a higher response rate was observed among patients with NEC/NET with high DLL3 expression, supporting DLL3 as a promising therapeutic target for the treatment of NEC/NET across primary disease sites, including treatment-emergent NEPC.